Pamela Munster, MD

Title(s)Professor, Medicine
SchoolSchool of Medicine
Address1450 Third Street, #282
San Francisco CA 94158
Phone415-502-3598
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    University of Bern1989
    Indiana University School of MedicineResidency1996Internal Medicine
    Memorial Sloan-Kettering Cancer CenterFellowship2000Hematology-Oncology

    Collapse Overview 

    Collapse Research 
    Collapse Research Activities and Funding
    Integrating Epigenetic Modulation into DNA Damage Repair
    NIH R01CA255613Jun 6, 2022 - May 31, 2027
    Role: Principal Investigator
    Developing silastic-silicone for the local delivery of hormonal therapy to prevent and treat breast cancer
    NIH R01CA220131Jul 1, 2017 - May 31, 2022
    Role: Principal Investigator
    Translating HP 13C MRI as a Novel Paradigm for Assessing Drug Target Inhibition
    NIH R01CA183071May 12, 2014 - Feb 29, 2020
    Role: Co-Principal Investigator
    The role of HDAC2 in hormone therapy resistance
    NIH R01CA152989Sep 19, 2011 - Jul 31, 2017
    Role: Principal Investigator
    The Role of Selective HDAC Enzymes in Drug Sensitivity
    NIH R01CA122657May 18, 2007 - Jul 31, 2012
    Role: Principal Investigator
    Potentiation of Topo Inhibitors by the HDACi, SAHA
    NIH R21CA112913Feb 6, 2006 - Jul 31, 2008
    Role: Principal Investigator
    Potentiation of Topo Inhibitors by HDAC Inhibitors
    NIH R21CA105875Sep 30, 2004 - May 31, 2007
    Role: Principal Investigator
    Cancer Center Support Grant
    NIH P30CA082103Aug 5, 1999 - May 31, 2023
    Role: Co-Investigator
    Description: Molecular Oncology Program

    Collapse ORNG Applications 
    Collapse Clinical Trials

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Estrogens and breast cancer. Ann Oncol. 2024 Nov 08. Kim J, Munster PN. PMID: 39522613.
      View in: PubMed   Mentions:
    2. Updated Survival Follow-Up for Phase Ib Trial of the Histone Deacetylase Inhibitor Abexinostat With Pazopanib in Patients With Solid Tumor Malignancies. JCO Precis Oncol. 2024 Nov; 8:e2400328. Tsang ES, Aggarwal RR, Bergsland EK, Calabrese S, Rozie A, Chaudhuri S, Dhawan MS, Pawlowska N, Grabowsky J, Thomas S, Munster PN. PMID: 39509670.
      View in: PubMed   Mentions:
    3. ORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Nab-Paclitaxel in Patients with Advanced Solid Tumors. Cancer Res Commun. 2024 Sep 01; 4(9):2415-2426. Chen CT, Khanna V, Kummar S, Abdul-Karim RM, Sommerhalder D, Tolcher AW, Ueno NT, Davis SL, Orr DW, Hamilton E, Patel MR, Spira AI, Jauhari S, Florou V, Duff M, Xu R, Wang J, Barkund SR, Zhou H, Pankov A, Kong W, Jahchan NS, Jackson EL, Sun JD, Junttila MR, Multani PS, Daemen A, Chow Maneval E, Munster PN. PMID: 39177285; PMCID: PMC11396014.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimalsCellsCTClinical Trials
    4. A Phase II Trial of the WEE1 Inhibitor Adavosertib in SETD2-Altered Advanced Solid Tumor Malignancies (NCI 10170). Cancer Res Commun. 2024 Jul 01; 4(7):1793-1801. Maldonado E, Rathmell WK, Shapiro GI, Takebe N, Rodon J, Mahalingam D, Trikalinos NA, Kalebasty AR, Parikh M, Boerner SA, Balido C, Krings G, Burns TF, Bergsland EK, Munster PN, Ashworth A, LoRusso P, Aggarwal RR. PMID: 38920407; PMCID: PMC11264598.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    5. Synthetic Lethality Beyond BRCA: A Phase I Study of Rucaparib and Irinotecan in Metastatic Solid Tumors With Homologous Recombination-Deficiency Mutations Beyond BRCA1/2. JCO Precis Oncol. 2024 Jun; 8:e2300494. Tsang ES, Dhawan MS, Pacaud R, Thomas S, Grabowsky J, Wilch L, Karipineni S, Kelley RK, Ko AH, Collisson E, Chapman JS, Ueda S, Bergsland EK, Munster P. PMID: 38865673.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    6. First-in-human Phase I Trial of TPST-1120, an Inhibitor of PPARα, as Monotherapy or in Combination with Nivolumab, in Patients with Advanced Solid Tumors. Cancer Res Commun. 2024 Apr 18; 4(4):1100-1110. Yarchoan M, Powderly JD, Bastos BR, Karasic TB, Crysler OV, Munster PN, McKean MA, Emens LA, Saenger YM, Ged Y, Stagg R, Smith S, Whiting CC, Moon A, Prasit P, Jenkins Y, Standifer N, Dubensky TW, Whiting SH, Ulahannan SV. PMID: 38551394; PMCID: PMC11025498.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    7. Correction: Combination of Itacitinib or Parsaclisib with Pembrolizumab in Patients with Advanced Solid Tumors: A Phase I Study. Cancer Res Commun. 2024 Mar 13; 4(3):785. Munster P, Iannotti N, Cho DC, Kirkwood JM, Villaruz LC, Gibney GT, Hodi FS, Mettu NB, Jones M, Bowman J, Smith M, Lakshminarayanan M, O'Day S. PMID: 38477691; PMCID: PMC10936421.
      View in: PubMed   Mentions:    Fields:    
    8. Phase I Study of Elraglusib (9-ING-41), a Glycogen Synthase Kinase-3β Inhibitor, as Monotherapy or Combined with Chemotherapy in Patients with Advanced Malignancies. Clin Cancer Res. 2024 02 01; 30(3):522-531. Carneiro BA, Cavalcante L, Mahalingam D, Saeed A, Safran H, Ma WW, Coveler AL, Powell S, Bastos B, Davis E, Sahai V, Mikrut W, Longstreth J, Smith S, Weisskittel T, Li H, Borden BA, Harvey RD, Sahebjam S, Cervantes A, Koukol A, Mazar AP, Steeghs N, Kurzrock R, Giles FJ, Munster P. PMID: 37982822.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    9. Combination of Itacitinib or Parsaclisib with Pembrolizumab in Patients with Advanced Solid Tumors: A Phase I Study. Cancer Res Commun. 2023 12 19; 3(12):2572-2584. Munster P, Iannotti N, Cho DC, Kirkwood JM, Villaruz LC, Gibney GT, Hodi FS, Mettu NB, Jones M, Bowman J, Smith M, Lakshminarayanan M, O'Day S. PMID: 38115208; PMCID: PMC10729644.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    10. A Phase 1b/2 Study of Alpelisib in Combination with Cetuximab in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. Target Oncol. 2023 Nov; 18(6):853-868. Razak ARA, Wang HM, Chang JY, Ahn MJ, Munster P, Blumenschein G, Solomon B, Lim DW, Hong RL, Pfister D, Saba NF, Lee SH, van Herpen C, Quadt C, Bootle D, Blumenstein L, Demanse D, Delord JP. PMID: 37875771; PMCID: PMC10663259.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    11. A long-term fulvestrant eluting implant is safe, non-toxic, and reduces the risk of breast cancer in in vivo models. Res Sq. 2023 Oct 23. Thomas S, Roche E, Desai P, Pawlowska N, Bauer D, Gingrich D, Hsu E, Deitchman AN, Aweeka F, Munster PN. PMID: 37961240; PMCID: PMC10635313.
      View in: PubMed   Mentions:
    12. First-in-human Evaluation of a Prostate-specific Membrane Antigen-targeted Near-infrared Fluorescent Small Molecule for Fluorescence-based Identification of Prostate Cancer in Patients with High-risk Prostate Cancer Undergoing Robotic-assisted Prostatectomy. Eur Urol Oncol. 2024 Feb; 7(1):63-72. Nguyen HG, van den Berg NS, Antaris AL, Xue L, Greenberg S, Rosenthal JW, Muchnik A, Klaassen A, Simko JP, Dutta S, Sorger JM, Munster P, Carroll PR. PMID: 37516587.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    13. Vaccinia (Smallpox) for the Treatment of Ovarian Cancer-Turning an Old Foe Into a Friend? JAMA Oncol. 2023 07 01; 9(7):894-896. Tsang ES, Munster PN. PMID: 37227718.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCellsPHPublic Health
    14. Pembrolizumab alone and pembrolizumab plus chemotherapy in previously treated, extrapulmonary poorly differentiated neuroendocrine carcinomas. Br J Cancer. 2023 08; 129(2):291-300. Raj N, Chan JA, Wang SJ, Aggarwal RR, Calabrese S, DeMore A, Fong L, Grabowsky J, Hope TA, Kolli KP, Mulvey CK, Munster PN, Perez K, Punn S, Reidy-Lagunes D, Von Fedak S, Zhang L, Bergsland EK. PMID: 37208512; PMCID: PMC10338510.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    15. ATM-SPARK: A GFP phase separation-based activity reporter of ATM. Sci Adv. 2023 03; 9(9):eade3760. Li X, Chung CI, Yang J, Chaudhuri S, Munster PN, Shu X. PMID: 36857446; PMCID: PMC9977181.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    16. Targeting RAD51-Mediated Homologous Recombination as a Treatment for Advanced Solid and Hematologic Malignancies: Opportunities and Challenges Ahead. Onco Targets Ther. 2022; 15:1509-1518. Tsang ES, Munster PN. PMID: 36536949; PMCID: PMC9758980.
      View in: PubMed   Mentions: 2  
    17. Overcoming Taxane Resistance: Preclinical and Phase 1 Studies of Relacorilant, a Selective Glucocorticoid Receptor Modulator, with Nab-Paclitaxel in Solid Tumors. Clin Cancer Res. 2022 08 02; 28(15):3214-3224. Munster PN, Greenstein AE, Fleming GF, Borazanci E, Sharma MR, Custodio JM, Tudor IC, Pashova HI, Shepherd SP, Grauer A, Sachdev JC. PMID: 35583817; PMCID: PMC9662918.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCTClinical Trials
    18. Phase II Study of Enzalutamide for Patients With Androgen Receptor-Positive Salivary Gland Cancers (Alliance A091404). J Clin Oncol. 2022 12 20; 40(36):4240-4249. Ho AL, Foster NR, Zoroufy AJ, Campbell JD, Worden F, Price K, Adkins D, Bowles DW, Kang H, Burtness B, Sherman E, Morton R, Morris LGT, Nadeem Z, Katabi N, Munster P, Schwartz GK. PMID: 35867947; PMCID: PMC9916043.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansCTClinical Trials
    19. A Phase IB Trial of the PI3K Inhibitor Alpelisib and Weekly Cisplatin in Patients with Solid Tumor Malignancies. Cancer Res Commun. 2022 07; 2(7):570-576. Tsang ES, Aggarwal RR, Dhawan MS, Bergsland EK, Alvarez EA, Calabrese S, Pacaud R, Garcia J, Fattah D, Thomas S, Grabowsky J, Moasser MM, Munster PN. PMID: 36923283; PMCID: PMC10010328.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    20. Late-onset Proteus syndrome with cerebriform connective tissue nevus and subsequent development of intraductal papilloma. Am J Med Genet A. 2022 09; 188(9):2766-2771. Modlin EW, Slavotinek AM, Darling TN, Lipkowitz S, Barr FG, Munster PN, Biesecker LG, Ours CA. PMID: 35441778; PMCID: PMC9519031.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    21. Malignant glioma subset from actuate 1801: Phase I/II study of 9-ING-41, GSK-3β inhibitor, monotherapy or combined with chemotherapy for refractory malignancies. Neurooncol Adv. 2022 Jan-Dec; 4(1):vdac012. Odia Y, Cavalcante L, Safran H, Powell SF, Munster PN, Ma WW, Carneiro BA, Bastos BR, Mikrut S, Mikrut W, Giles FJ, Sahebjam S. PMID: 35402914; PMCID: PMC8989389.
      View in: PubMed   Mentions: 2  
    22. Glucocorticoid Receptor Antagonism Upregulates Somatostatin Receptor Subtype 2 Expression in ACTH-Producing Neuroendocrine Tumors: New Insight Based on the Selective Glucocorticoid Receptor Modulator Relacorilant. Front Endocrinol (Lausanne). 2021; 12:793262. Pivonello R, Munster PN, Terzolo M, Ferrigno R, Simeoli C, Puglisi S, Bali U, Moraitis AG. PMID: 35058882; PMCID: PMC8764187.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansAnimalsCells
    23. Sotorasib for previously treated colorectal cancers with KRASG12C mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trial. Lancet Oncol. 2022 01; 23(1):115-124. Fakih MG, Kopetz S, Kuboki Y, Kim TW, Munster PN, Krauss JC, Falchook GS, Han SW, Heinemann V, Muro K, Strickler JH, Hong DS, Denlinger CS, Girotto G, Lee MA, Henary H, Tran Q, Park JK, Ngarmchamnanrith G, Prenen H, Price TJ. PMID: 34919824.
      View in: PubMed   Mentions: 106     Fields:    Translation:HumansCTClinical Trials
    24. A Phase I Dose-Escalation and Expansion Study of Telaglenastat in Patients with Advanced or Metastatic Solid Tumors. Clin Cancer Res. 2021 09 15; 27(18):4994-5003. Harding JJ, Telli M, Munster P, Voss MH, Infante JR, DeMichele A, Dunphy M, Le MH, Molineaux C, Orford K, Parlati F, Whiting SH, Bennett MK, Tannir NM, Meric-Bernstam F. PMID: 34285061; PMCID: PMC9401498.
      View in: PubMed   Mentions: 24     Fields:    Translation:Humans
    25. Inhibition of MET Signaling with Ficlatuzumab in Combination with Chemotherapy in Refractory AML: Clinical Outcomes and High-Dimensional Analysis. Blood Cancer Discov. 2021 09; 2(5):434-449. Wang VE, Blaser BW, Patel RK, Behbehani GK, Rao AA, Durbin-Johnson B, Jiang T, Logan AC, Settles M, Mannis GN, Olin R, Damon LE, Martin TG, Sayre PH, Gaensler KM, McMahon E, Flanders M, Weinberg V, Ye CJ, Carbone DP, Munster PN, Fragiadakis GK, McCormick F, Andreadis C. PMID: 34514432; PMCID: PMC8425277.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    26. Specialized computational methods for denoising, B1 correction, and kinetic modeling in hyperpolarized 13 C MR EPSI studies of liver tumors. Magn Reson Med. 2021 11; 86(5):2402-2411. Lee PM, Chen HY, Gordon JW, Zhu Z, Larson PEZ, Dwork N, Van Criekinge M, Carvajal L, Ohliger MA, Wang ZJ, Xu D, Kurhanewicz J, Bok RA, Aggarwal R, Munster PN, Vigneron DB. PMID: 34216051; PMCID: PMC8565779.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    27. Phase 1b trial of isatuximab, an anti-CD38 monoclonal antibody, in combination with carfilzomib as treatment of relapsed/refractory multiple myeloma. Cancer. 2021 06 01; 127(11):1816-1826. Martin TG, Shah N, Richter J, Vesole DH, Wong SW, Huang CY, Madduri D, Jagannath S, Siegel DS, Biran N, Wolf JL, Parekh S, Cho HJ, Munster P, Richard S, Ziti-Ljajic S, Chari A. PMID: 33735504; PMCID: PMC8252002.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    28. Immunotherapy in breast cancer: A clinician's perspective. J Natl Cancer Cent. 2021 Jun; 1(2):47-57. Chaudhuri S, Thomas S, Munster P. PMID: 39035768; PMCID: PMC11256727.
      View in: PubMed   Mentions: 7  
    29. Transcriptional analysis of metastatic uveal melanoma survival nominates NRP1 as a therapeutic target. Melanoma Res. 2021 02 01; 31(1):27-37. Bao R, Surriga O, Olson DJ, Allred JB, Strand CA, Zha Y, Carll T, Labadie BW, Bastos BR, Butler M, Hogg D, Musi E, Ambrosini G, Munster P, Schwartz GK, Luke JJ. PMID: 33170593; PMCID: PMC7755667.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    30. A phase I trial adding poly(ADP-ribose) polymerase inhibitor veliparib to induction carboplatin-paclitaxel in patients with head and neck squamous cell carcinoma: Alliance A091101. Oral Oncol. 2021 03; 114:105171. Jelinek MJ, Foster NR, Zoroufy AJ, Schwartz GK, Munster PN, Seiwert TY, de Souza JA, Vokes EE. PMID: 33513474; PMCID: PMC7933088.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCTClinical Trials
    31. Phase I study of liposomal irinotecan in patients with metastatic breast cancer: findings from the expansion phase. Breast Cancer Res Treat. 2021 Feb; 185(3):759-771. Sachdev JC, Munster P, Northfelt DW, Han HS, Ma C, Maxwell F, Wang T, Belanger B, Zhang B, Moore Y, Thiagalingam A, Anders C. PMID: 33201358; PMCID: PMC7921078.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCTClinical Trials
    32. Commentary: GSK-3 Inhibition as a Therapeutic Approach Against SARs CoV2: Dual Benefit of Inhibiting Viral Replication While Potentiating the Immune Response. Front Immunol. 2020; 11:595289. De Souza A, Tavora FA, Mahalingam D, Munster PN, Safran HP, El-Deiry WS, Carneiro BA. PMID: 33193448; PMCID: PMC7604263.
      View in: PubMed   Mentions: 2     Fields:    
    33. Safety and clinical activity of intratumoral MEDI9197 alone and in combination with durvalumab and/or palliative radiation therapy in patients with advanced solid tumors. J Immunother Cancer. 2020 10; 8(2). Siu L, Brody J, Gupta S, Marabelle A, Jimeno A, Munster P, Grilley-Olson J, Rook AH, Hollebecque A, Wong RKS, Welsh JW, Wu Y, Morehouse C, Hamid O, Walcott F, Cooper ZA, Kumar R, Ferté C, Hong DS. PMID: 33037117; PMCID: PMC7549442.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansAnimals
    34. KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors. N Engl J Med. 2020 09 24; 383(13):1207-1217. Hong DS, Fakih MG, Strickler JH, Desai J, Durm GA, Shapiro GI, Falchook GS, Price TJ, Sacher A, Denlinger CS, Bang YJ, Dy GK, Krauss JC, Kuboki Y, Kuo JC, Coveler AL, Park K, Kim TW, Barlesi F, Munster PN, Ramalingam SS, Burns TF, Meric-Bernstam F, Henary H, Ngang J, Ngarmchamnanrith G, Kim J, Houk BE, Canon J, Lipford JR, Friberg G, Lito P, Govindan R, Li BT. PMID: 32955176; PMCID: PMC7571518.
      View in: PubMed   Mentions: 644     Fields:    Translation:HumansCTClinical Trials
    35. Exhausted T cell signature predicts immunotherapy response in ER-positive breast cancer. Nat Commun. 2020 07 17; 11(1):3584. Terranova-Barberio M, Pawlowska N, Dhawan M, Moasser M, Chien AJ, Melisko ME, Rugo H, Rahimi R, Deal T, Daud A, Rosenblum MD, Thomas S, Munster PN. PMID: 32681091; PMCID: PMC7367885.
      View in: PubMed   Mentions: 82     Fields:    Translation:HumansCellsCTClinical Trials
    36. Author Correction: Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer. Nat Commun. 2020 05 18; 11(1):2543. Färkkilä A, Gulhan DC, Casado J, Jacobson CA, Nguyen H, Kochupurakkal B, Maliga Z, Yapp C, Chen YA, Schapiro D, Zhou Y, Graham JR, Dezube BJ, Munster P, Santagata S, Garcia E, Rodig S, Lako A, Chowdhury D, Shapiro GI, Matulonis UA, Park PJ, Hautaniemi S, Sorger PK, Swisher EM, D'Andrea AD, Konstantinopoulos PA. PMID: 32424117; PMCID: PMC7235235.
      View in: PubMed   Mentions: 4     Fields:    
    37. Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer. Nat Commun. 2020 03 19; 11(1):1459. Färkkilä A, Gulhan DC, Casado J, Jacobson CA, Nguyen H, Kochupurakkal B, Maliga Z, Yapp C, Chen YA, Schapiro D, Zhou Y, Graham JR, Dezube BJ, Munster P, Santagata S, Garcia E, Rodig S, Lako A, Chowdhury D, Shapiro GI, Matulonis UA, Park PJ, Hautaniemi S, Sorger PK, Swisher EM, D'Andrea AD, Konstantinopoulos PA. PMID: 32193378; PMCID: PMC7081234.
      View in: PubMed   Mentions: 139     Fields:    Translation:HumansCellsCTClinical Trials
    38. First-In-Human Phase I Study Of A Dual mTOR Kinase And DNA-PK Inhibitor (CC-115) In Advanced Malignancy. Cancer Manag Res. 2019; 11:10463-10476. Munster P, Mita M, Mahipal A, Nemunaitis J, Massard C, Mikkelsen T, Cruz C, Paz-Ares L, Hidalgo M, Rathkopf D, Blumenschein G, Smith DC, Eichhorst B, Cloughesy T, Filvaroff EH, Li S, Raymon H, de Haan H, Hege K, Bendell JC. PMID: 31853198; PMCID: PMC6916675.
      View in: PubMed   Mentions: 51  
    39. Before Consent: Qualitative Analysis of Deliberations of Patients With Advanced Cancer About Early-Phase Clinical Trials. JCO Oncol Pract. 2020 01; 16(1):e56-e63. Garrett SB, Matthews TM, Abramson CM, Koenig CJ, Hlubocky FJ, Daugherty CK, Munster PN, Dohan D. PMID: 31603726; PMCID: PMC6993554.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    40. Reply: Strategies to Prevent Cardiotoxicity. J Am Coll Cardiol. 2019 10 01; 74(13):1737-1738. Guglin M, Tamura R, Krischer J, Munster PN. PMID: 31558261.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    41. Randomized Phase II Trial and Tumor Mutational Spectrum Analysis from Cabozantinib versus Chemotherapy in Metastatic Uveal Melanoma (Alliance A091201). Clin Cancer Res. 2020 02 15; 26(4):804-811. Luke JJ, Olson DJ, Allred JB, Strand CA, Bao R, Zha Y, Carll T, Labadie BW, Bastos BR, Butler MO, Hogg D, Munster PN, Schwartz GK. PMID: 31558480; PMCID: PMC7055933.
      View in: PubMed   Mentions: 26     Fields:    Translation:HumansCTClinical Trials
    42. A phase 2 study of an oral mTORC1/mTORC2 kinase inhibitor (CC-223) for non-pancreatic neuroendocrine tumors with or without carcinoid symptoms. PLoS One. 2019; 14(9):e0221994. Wolin E, Mita A, Mahipal A, Meyer T, Bendell J, Nemunaitis J, Munster PN, Paz-Ares L, Filvaroff EH, Li S, Hege K, de Haan H, Mita M. PMID: 31527867; PMCID: PMC6748410.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCTClinical Trials
    43. Maintenance lenalidomide in primary CNS lymphoma. Ann Oncol. 2019 08 01; 30(8):1397-1398. Rubenstein JL, Geng H, Vu K, Mannis G, Formaker P, Hwang J, Munster PN, Damato B. PMID: 31046114; PMCID: PMC8887569.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    44. Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma. JAMA Oncol. 2019 Aug 01; 5(8):1141-1149. Konstantinopoulos PA, Waggoner S, Vidal GA, Mita M, Moroney JW, Holloway R, Van Le L, Sachdev JC, Chapman-Davis E, Colon-Otero G, Penson RT, Matulonis UA, Kim YB, Moore KN, Swisher EM, Färkkilä A, D'Andrea A, Stringer-Reasor E, Wang J, Buerstatte N, Arora S, Graham JR, Bobilev D, Dezube BJ, Munster P. PMID: 31194228; PMCID: PMC6567832.
      View in: PubMed   Mentions: 238     Fields:    
    45. A Phase 1b/2 Study of the Bruton Tyrosine Kinase Inhibitor Ibrutinib and the PD-L1 Inhibitor Durvalumab in Patients with Pretreated Solid Tumors. Oncology. 2019; 97(2):102-111. Hong D, Rasco D, Veeder M, Luke JJ, Chandler J, Balmanoukian A, George TJ, Munster P, Berlin JD, Gutierrez M, Mita A, Wakelee H, Samakoglu S, Guan S, Dimery I, Graef T, Borazanci E. PMID: 31230047.
      View in: PubMed   Mentions: 45     Fields:    Translation:HumansCTClinical Trials
    46. Randomized Trial of Lisinopril Versus Carvedilol to Prevent Trastuzumab Cardiotoxicity in Patients With Breast Cancer. J Am Coll Cardiol. 2019 06 11; 73(22):2859-2868. Guglin M, Krischer J, Tamura R, Fink A, Bello-Matricaria L, McCaskill-Stevens W, Munster PN. PMID: 31171092; PMCID: PMC6557296.
      View in: PubMed   Mentions: 125     Fields:    Translation:Humans
    47. Histone Deacetylase Inhibition with Panobinostat Combined with Intensive Induction Chemotherapy in Older Patients with Acute Myeloid Leukemia: Phase I Study Results. Clin Cancer Res. 2019 08 15; 25(16):4917-4923. Wieduwilt MJ, Pawlowska N, Thomas S, Olin R, Logan AC, Damon LE, Martin T, Kang M, Sayre PH, Boyer W, Gaensler KML, Anderson K, Munster PN, Andreadis C. PMID: 31152020.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCellsCTClinical Trials
    48. A dual pathway inhibition strategy using BKM120 combined with vemurafenib is poorly tolerated in BRAF V600E/K mutant advanced melanoma. Pigment Cell Melanoma Res. 2019 07; 32(4):603-606. Algazi AP, Rotow J, Posch C, Ortiz-Urda S, Pelayo A, Munster PN, Daud A. PMID: 30801911.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    49. Coil combination methods for multi-channel hyperpolarized 13C imaging data from human studies. J Magn Reson. 2019 04; 301:73-79. Zhu Z, Zhu X, Ohliger MA, Tang S, Cao P, Carvajal L, Autry AW, Li Y, Kurhanewicz J, Chang S, Aggarwal R, Munster P, Xu D, Larson PEZ, Vigneron DB, Gordon JW. PMID: 30851668; PMCID: PMC7170546.
      View in: PubMed   Mentions: 20     Fields:    Translation:Humans
    50. Safety and pharmacokinetics of MM-302, a HER2-targeted antibody-liposomal doxorubicin conjugate, in patients with advanced HER2-positive breast cancer: a phase 1 dose-escalation study. Br J Cancer. 2018 10; 119(9):1086-1093. Munster P, Krop IE, LoRusso P, Ma C, Siegel BA, Shields AF, Molnár I, Wickham TJ, Reynolds J, Campbell K, Hendriks BS, Adiwijaya BS, Geretti E, Moyo V, Miller KD. PMID: 30361524; PMCID: PMC6219487.
      View in: PubMed   Mentions: 33     Fields:    Translation:HumansCTClinical Trials
    51. Phase 1 investigation of lenalidomide/rituximab plus outcomes of lenalidomide maintenance in relapsed CNS lymphoma. Blood Adv. 2018 07 10; 2(13):1595-1607. Rubenstein JL, Geng H, Fraser EJ, Formaker P, Chen L, Sharma J, Killea P, Choi K, Ventura J, Kurhanewicz J, Lowell C, Hwang J, Treseler P, Sneed PK, Li J, Wang X, Chen N, Gangoiti J, Munster PN, Damato B. PMID: 29986852; PMCID: PMC6039666.
      View in: PubMed   Mentions: 65     Fields:    Translation:HumansCTClinical Trials
    52. A phase I dose-escalation and dose-expansion study of brontictuzumab in subjects with selected solid tumors. Ann Oncol. 2018 07 01; 29(7):1561-1568. Ferrarotto R, Eckhardt G, Patnaik A, LoRusso P, Faoro L, Heymach JV, Kapoun AM, Xu L, Munster P. PMID: 29726923.
      View in: PubMed   Mentions: 65     Fields:    Translation:HumansCTClinical Trials
    53. Phase I Study of CC-486 Alone and in Combination with Carboplatin or nab-Paclitaxel in Patients with Relapsed or Refractory Solid Tumors. Clin Cancer Res. 2018 09 01; 24(17):4072-4080. Von Hoff DD, Rasco DW, Heath EI, Munster PN, Schellens JHM, Isambert N, Le Tourneau C, O'Neil B, Mathijssen RHJ, Lopez-Martin JA, Edenfield WJ, Martin M, LoRusso PM, Bray GL, DiMartino J, Nguyen A, Liu K, Laille E, Bendell JC. PMID: 29764853; PMCID: PMC6853187.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCTClinical Trials
    54. Gonadotropin-Releasing Hormone Agonists During Chemotherapy for Preservation of Ovarian Function and Fertility in Premenopausal Patients With Early Breast Cancer: A Systematic Review and Meta-Analysis of Individual Patient-Level Data. J Clin Oncol. 2018 07 01; 36(19):1981-1990. Lambertini M, Moore HCF, Leonard RCF, Loibl S, Munster P, Bruzzone M, Boni L, Unger JM, Anderson RA, Mehta K, Minton S, Poggio F, Albain KS, Adamson DJA, Gerber B, Cripps A, Bertelli G, Seiler S, Ceppi M, Partridge AH, Del Mastro L. PMID: 29718793; PMCID: PMC6804855.
      View in: PubMed   Mentions: 110     Fields:    Translation:Humans
    55. Technique development of 3D dynamic CS-EPSI for hyperpolarized 13 C pyruvate MR molecular imaging of human prostate cancer. Magn Reson Med. 2018 11; 80(5):2062-2072. Chen HY, Larson PEZ, Gordon JW, Bok RA, Ferrone M, van Criekinge M, Carvajal L, Cao P, Pauly JM, Kerr AB, Park I, Slater JB, Nelson SJ, Munster PN, Aggarwal R, Kurhanewicz J, Vigneron DB. PMID: 29575178; PMCID: PMC6107425.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansAnimals
    56. Local delivery of hormonal therapy with silastic tubing for prevention and treatment of breast cancer. Sci Rep. 2018 01 08; 8(1):92. Park J, Thomas S, Zhong AY, Wolfe AR, Krings G, Terranova-Barberio M, Pawlowska N, Benet LZ, Munster PN. PMID: 29311658; PMCID: PMC5758798.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansAnimalsCells
    57. HDAC inhibition potentiates immunotherapy in triple negative breast cancer. Oncotarget. 2017 Dec 26; 8(69):114156-114172. Terranova-Barberio M, Thomas S, Ali N, Pawlowska N, Park J, Krings G, Rosenblum MD, Budillon A, Munster PN. PMID: 29371976; PMCID: PMC5768393.
      View in: PubMed   Mentions: 96     Fields:    
    58. Host histone acetylation unlocks HDAC inhibitor potential. Oncotarget. 2017 Dec 05; 8(63):106161-106162. Terranova-Barberio M, Thomas S, Munster PN. PMID: 29290932; PMCID: PMC5739717.
      View in: PubMed   Mentions: 1     Fields:    
    59. Heterogeneous drug penetrance of veliparib and carboplatin measured in triple negative breast tumors. Breast Cancer Res. 2017 Sep 11; 19(1):107. Bartelink IH, Prideaux B, Krings G, Wilmes L, Lee PRE, Bo P, Hann B, Coppé JP, Heditsian D, Swigart-Brown L, Jones EF, Magnitsky S, Keizer RJ, de Vries N, Rosing H, Pawlowska N, Thomas S, Dhawan M, Aggarwal R, Munster PN, Esserman LJ, Ruan W, Wu AHB, Yee D, Dartois V, Savic RM, Wolf DM, van 't Veer L. PMID: 28893315; PMCID: PMC5594551.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansAnimalsCells
    60. Autologous Fat Grafting as a Novel Antiestrogen Vehicle for the Treatment of Breast Cancer. Plast Reconstr Surg. 2017 Sep; 140(3):537-544. Thomas S, Chen S, Sbitany H, Kwon E, Piper M, Park J, Terranova Barberio M, Pawlowska N, Munster PN. PMID: 28841614; PMCID: PMC5604844.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansAnimalsCells
    61. Differential Toxicity in Patients with and without DNA Repair Mutations: Phase I Study of Carboplatin and Talazoparib in Advanced Solid Tumors. Clin Cancer Res. 2017 Nov 01; 23(21):6400-6410. Dhawan MS, Bartelink IH, Aggarwal RR, Leng J, Zhang JZ, Pawlowska N, Terranova-Barberio M, Grabowsky JA, Gewitz A, Chien AJ, Moasser M, Kelley RK, Maktabi T, Thomas S, Munster PN. PMID: 28790114.
      View in: PubMed   Mentions: 40     Fields:    Translation:HumansCellsCTClinical Trials
    62. What advanced cancer patients with limited treatment options know about clinical research: a qualitative study. Support Care Cancer. 2017 10; 25(10):3235-3242. Garrett SB, Koenig CJ, Trupin L, Hlubocky FJ, Daugherty CK, Reinert A, Munster P, Dohan D. PMID: 28488050; PMCID: PMC5680157.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    63. A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma. Blood. 2017 06 22; 129(25):3294-3303. Martin T, Baz R, Benson DM, Lendvai N, Wolf J, Munster P, Lesokhin AM, Wack C, Charpentier E, Campana F, Vij R. PMID: 28483761; PMCID: PMC5482100.
      View in: PubMed   Mentions: 79     Fields:    Translation:HumansCTClinical Trials
    64. Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal. Ann Oncol. 2017 05 01; 28(5):1036-1041. Ott PA, Piha-Paul SA, Munster P, Pishvaian MJ, van Brummelen EMJ, Cohen RB, Gomez-Roca C, Ejadi S, Stein M, Chan E, Simonelli M, Morosky A, Saraf S, Emancipator K, Koshiji M, Bennouna J. PMID: 28453692; PMCID: PMC5406758.
      View in: PubMed   Mentions: 106     Fields:    Translation:HumansCTClinical Trials
    65. Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC. Cancer Immunol Res. 2017 05; 5(5):417-424. Tumeh PC, Hellmann MD, Hamid O, Tsai KK, Loo KL, Gubens MA, Rosenblum M, Harview CL, Taube JM, Handley N, Khurana N, Nosrati A, Krummel MF, Tucker A, Sosa EV, Sanchez PJ, Banayan N, Osorio JC, Nguyen-Kim DL, Chang J, Shintaku IP, Boasberg PD, Taylor EJ, Munster PN, Algazi AP, Chmielowski B, Dummer R, Grogan TR, Elashoff D, Hwang J, Goldinger SM, Garon EB, Pierce RH, Daud A. PMID: 28411193; PMCID: PMC5749922.
      View in: PubMed   Mentions: 296     Fields:    Translation:HumansCellsCTClinical Trials
    66. Lisinopril or Coreg CR in reducing cardiotoxicity in women with breast cancer receiving trastuzumab: A rationale and design of a randomized clinical trial. Am Heart J. 2017 Jun; 188:87-92. Guglin M, Munster P, Fink A, Krischer J. PMID: 28577685; PMCID: PMC5458618.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCTClinical Trials
    67. 64Cu-MM-302 Positron Emission Tomography Quantifies Variability of Enhanced Permeability and Retention of Nanoparticles in Relation to Treatment Response in Patients with Metastatic Breast Cancer. Clin Cancer Res. 2017 Aug 01; 23(15):4190-4202. Lee H, Shields AF, Siegel BA, Miller KD, Krop I, Ma CX, LoRusso PM, Munster PN, Campbell K, Gaddy DF, Leonard SC, Geretti E, Blocker SJ, Kirpotin DB, Moyo V, Wickham TJ, Hendriks BS. PMID: 28298546; PMCID: PMC6790129.
      View in: PubMed   Mentions: 135     Fields:    Translation:HumansCTClinical Trials
    68. Glucocorticoid receptor expression in 20 solid tumor types using immunohistochemistry assay. Cancer Manag Res. 2017; 9:65-72. Block TS, Murphy TI, Munster PN, Nguyen DP, Lynch FJ. PMID: 28293120; PMCID: PMC5345989.
      View in: PubMed   Mentions: 20  
    69. Inhibiting Histone Deacetylase as a Means to Reverse Resistance to Angiogenesis Inhibitors: Phase I Study of Abexinostat Plus Pazopanib in Advanced Solid Tumor Malignancies. J Clin Oncol. 2017 Apr 10; 35(11):1231-1239. Aggarwal R, Thomas S, Pawlowska N, Bartelink I, Grabowsky J, Jahan T, Cripps A, Harb A, Leng J, Reinert A, Mastroserio I, Truong TG, Ryan CJ, Munster PN. PMID: 28221861; PMCID: PMC5791833.
      View in: PubMed   Mentions: 44     Fields:    Translation:HumansCellsCTClinical Trials
    70. Activating NOTCH1 Mutations Define a Distinct Subgroup of Patients With Adenoid Cystic Carcinoma Who Have Poor Prognosis, Propensity to Bone and Liver Metastasis, and Potential Responsiveness to Notch1 Inhibitors. J Clin Oncol. 2017 Jan 20; 35(3):352-360. Ferrarotto R, Mitani Y, Diao L, Guijarro I, Wang J, Zweidler-McKay P, Bell D, William WN, Glisson BS, Wick MJ, Kapoun AM, Patnaik A, Eckhardt G, Munster P, Faoro L, Dupont J, Lee JJ, Futreal A, El-Naggar AK, Heymach JV. PMID: 27870570; PMCID: PMC5456373.
      View in: PubMed   Mentions: 91     Fields:    Translation:HumansAnimalsCells
    71. Randomized phase 1 crossover study assessing the bioequivalence of capsule and tablet formulations of dovitinib (TKI258) in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2016 Nov; 78(5):921-927. Sarantopoulos J, Goel S, Chung V, Munster P, Pant S, Patel MR, Infante J, Tawbi H, Becerra C, Bruce J, Kabbinavar F, Lockhart AC, Tan E, Yang S, Carlson G, Scott JW, Sharma S. PMID: 27681579.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    72. Effect of Temporary Ovarian Suppression on Chemotherapy-Induced Amenorrhea, Pregnancy, and Outcome. JAMA Oncol. 2016 08 01; 2(8):1089-90. Munster PN. PMID: 27228206.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    73. Interest in initiating an early phase clinical trial: results of a longitudinal study of advanced cancer patients. Psychooncology. 2017 Oct; 26(10):1604-1610. Dunn LB, Wiley J, Garrett S, Hlubocky F, Daugherty C, Trupin L, Munster P, Dohan D. PMID: 27233054.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    74. Epigenetic modifiers in immunotherapy: a focus on checkpoint inhibitors. Immunotherapy. 2016 06; 8(6):705-19. Terranova-Barberio M, Thomas S, Munster PN. PMID: 27197539; PMCID: PMC5705793.
      View in: PubMed   Mentions: 32     Fields:    Translation:HumansAnimalsCells
    75. A phase I trial of panobinostat and epirubicin in solid tumors with a dose expansion in patients with sarcoma. Ann Oncol. 2016 05; 27(5):947-52. Thomas S, Aggarwal R, Jahan T, Ryan C, Troung T, Cripps AM, Raha P, Thurn KT, Chen S, Grabowsky JA, Park J, Hwang J, Daud A, Munster PN. PMID: 26903311; PMCID: PMC4843187.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCellsCTClinical Trials
    76. A phase 1b study of the Akt-inhibitor MK-2206 in combination with weekly paclitaxel and trastuzumab in patients with advanced HER2-amplified solid tumor malignancies. Breast Cancer Res Treat. 2016 Feb; 155(3):521-30. Chien AJ, Cockerill A, Fancourt C, Schmidt E, Moasser MM, Rugo HS, Melisko ME, Ko AH, Kelley RK, Korn WM, Esserman LJ, van't Veer L, Yau C, Wolf DM, Munster PN. PMID: 26875185.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansCTClinical Trials
    77. Can ovarian suppression with gonadotropin-releasing hormone analogs (GnRHa) preserve fertility in cancer patients? Ann Oncol. 2016 Feb; 27(2):357. Rodriguez-Wallberg K, Turan V, Munster P, Oktay K. PMID: 26609009; PMCID: PMC6267935.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    78. First-in-Human Phase I Study of GSK2126458, an Oral Pan-Class I Phosphatidylinositol-3-Kinase Inhibitor, in Patients with Advanced Solid Tumor Malignancies. Clin Cancer Res. 2016 Apr 15; 22(8):1932-9. Munster P, Aggarwal R, Hong D, Schellens JH, van der Noll R, Specht J, Witteveen PO, Werner TL, Dees EC, Bergsland E, Agarwal N, Kleha JF, Durante M, Adams L, Smith DA, Lampkin TA, Morris SR, Kurzrock R. PMID: 26603258.
      View in: PubMed   Mentions: 49     Fields:    Translation:HumansCTClinical Trials
    79. Association of tamoxifen use and ovarian function in patients with invasive or pre-invasive breast cancer. Breast Cancer Res Treat. 2015 Aug; 153(1):173-81. Chien AJ, Duralde E, Hwang R, Tsung K, Kao CN, Rugo HS, Melisko ME, Esserman LJ, Munster PN, Cedars M, Kerlikowske K, McCulloch CE, Rosen MP. PMID: 26208485.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    80. Results of a phase 1 trial combining ridaforolimus and MK-0752 in patients with advanced solid tumours. Eur J Cancer. 2015 Sep; 51(14):1865-73. Piha-Paul SA, Munster PN, Hollebecque A, Argilés G, Dajani O, Cheng JD, Wang R, Swift A, Tosolini A, Gupta S. PMID: 26199039; PMCID: PMC5693226.
      View in: PubMed   Mentions: 31     Fields:    Translation:HumansCellsCTClinical Trials
    81. A Phase I Trial of Combined Ridaforolimus and MK-2206 in Patients with Advanced Malignancies. Clin Cancer Res. 2015 Dec 01; 21(23):5235-44. Gupta S, Argilés G, Munster PN, Hollebecque A, Dajani O, Cheng JD, Wang R, Swift A, Tosolini A, Piha-Paul SA. PMID: 26187616.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCellsCTClinical Trials
    82. A phase I dose-escalation study to assess safety, tolerability, pharmacokinetics, and preliminary efficacy of the dual mTORC1/mTORC2 kinase inhibitor CC-223 in patients with advanced solid tumors or multiple myeloma. Cancer. 2015 Oct 01; 121(19):3481-90. Bendell JC, Kelley RK, Shih KC, Grabowsky JA, Bergsland E, Jones S, Martin T, Infante JR, Mischel PS, Matsutani T, Xu S, Wong L, Liu Y, Wu X, Mortensen DS, Chopra R, Hege K, Munster PN. PMID: 26177599; PMCID: PMC4832308.
      View in: PubMed   Mentions: 43     Fields:    Translation:HumansCTClinical Trials
    83. Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas. Cancer Discov. 2015 Oct; 5(10):1040-8. Zill OA, Greene C, Sebisanovic D, Siew LM, Leng J, Vu M, Hendifar AE, Wang Z, Atreya CE, Kelley RK, Van Loon K, Ko AH, Tempero MA, Bivona TG, Munster PN, Talasaz A, Collisson EA. PMID: 26109333; PMCID: PMC4592417.
      View in: PubMed   Mentions: 131     Fields:    Translation:Humans
    84. More Options for Fertility Preservation for Patients With Cancer. J Clin Oncol. 2015 Aug 01; 33(22):2413-5. Munster PN. PMID: 26101241.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    85. Ovarian protection during adjuvant chemotherapy. N Engl J Med. 2015 06 04; 372(23):2268-9. Oktay K, Rodriguez-Wallberg K, Munster P. PMID: 26039611.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    86. Combined histone deacetylase inhibition and tamoxifen induces apoptosis in tamoxifen-resistant breast cancer models, by reversing Bcl-2 overexpression. Breast Cancer Res. 2015 Feb 25; 17:26. Raha P, Thomas S, Thurn KT, Park J, Munster PN. PMID: 25848915; PMCID: PMC4367983.
      View in: PubMed   Mentions: 50     Fields:    Translation:HumansAnimalsCells
    87. Phase I dose-escalation trial of checkpoint kinase 1 inhibitor MK-8776 as monotherapy and in combination with gemcitabine in patients with advanced solid tumors. J Clin Oncol. 2015 Mar 20; 33(9):1060-6. Daud AI, Ashworth MT, Strosberg J, Goldman JW, Mendelson D, Springett G, Venook AP, Loechner S, Rosen LS, Shanahan F, Parry D, Shumway S, Grabowsky JA, Freshwater T, Sorge C, Kang SP, Isaacs R, Munster PN. PMID: 25605849.
      View in: PubMed   Mentions: 100     Fields:    Translation:HumansCellsCTClinical Trials
    88. Epigenetic modulation with histone deacetylase inhibitors in combination with immunotherapy. Epigenomics. 2015; 7(4):641-52. Park J, Thomas S, Munster PN. PMID: 26111034.
      View in: PubMed   Mentions: 28     Fields:    Translation:HumansAnimals
    89. Impact of patient ethnicity on the metabolic and immunologic effects of PI3K-mTOR pathway inhibition in patients with solid tumor malignancies. Cancer Chemother Pharmacol. 2014 Aug; 74(2):359-65. Aggarwal R, Grabowsky J, Strait N, Cockerill A, Munster P. PMID: 24934865; PMCID: PMC5257275.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    90. New protein kinase inhibitors in breast cancer: afatinib and neratinib. Expert Opin Pharmacother. 2014 Jun; 15(9):1277-88. Zhang X, Munster PN. PMID: 24787047.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansAnimals
    91. Phase I dose-escalation study of 5-day intermittent oral lapatinib therapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer. J Clin Oncol. 2014 May 10; 32(14):1472-9. Chien AJ, Munster PN, Melisko ME, Rugo HS, Park JW, Goga A, Auerback G, Khanafshar E, Ordovas K, Koch KM, Moasser MM. PMID: 24711549; PMCID: PMC4017711.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansCTClinical Trials
    92. Phase 1b study of safety, tolerability and efficacy of R1507, a monoclonal antibody to IGF-1R in combination with multiple standard oncology regimens in patients with advanced solid malignancies. Cancer Chemother Pharmacol. 2014 Mar; 73(3):467-73. Mahadevan D, Sutton GR, Arteta-Bulos R, Bowden CJ, Miller PJ, Swart RE, Walker MS, Haluska P, Munster PN, Marshall J, Hamid O, Kurzrock R. PMID: 24390424.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansCTClinical Trials
    93. Complement activation and intraventricular rituximab distribution in recurrent central nervous system lymphoma. Clin Cancer Res. 2014 Feb 15; 20(4):1029-41. Kadoch C, Li J, Wong VS, Chen L, Cha S, Munster P, Lowell CA, Shuman MA, Rubenstein JL. PMID: 24190981; PMCID: PMC3944388.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    94. A phase I, randomized, open-label study of the multiple-dose pharmacokinetics of vemurafenib in patients with BRAF V600E mutation-positive metastatic melanoma. Cancer Chemother Pharmacol. 2014 Jan; 73(1):103-11. Grippo JF, Zhang W, Heinzmann D, Yang KH, Wong J, Joe AK, Munster P, Sarapa N, Daud A. PMID: 24178368.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansCTClinical Trials
    95. Metabolic imaging of patients with prostate cancer using hyperpolarized [1-¹³C]pyruvate. Sci Transl Med. 2013 Aug 14; 5(198):198ra108. Nelson SJ, Kurhanewicz J, Vigneron DB, Larson PE, Harzstark AL, Ferrone M, van Criekinge M, Chang JW, Bok R, Park I, Reed G, Carvajal L, Small EJ, Munster P, Weinberg VK, Ardenkjaer-Larsen JH, Chen AP, Hurd RE, Odegardstuen LI, Robb FJ, Tropp J, Murray JA. PMID: 23946197; PMCID: PMC4201045.
      View in: PubMed   Mentions: 630     Fields:    Translation:Humans
    96. Histone deacetylase regulation of ATM-mediated DNA damage signaling. Mol Cancer Ther. 2013 Oct; 12(10):2078-87. Thurn KT, Thomas S, Raha P, Qureshi I, Munster PN. PMID: 23939379; PMCID: PMC3821775.
      View in: PubMed   Mentions: 64     Fields:    Translation:HumansCells
    97. Efficacy of histone deacetylase and estrogen receptor inhibition in breast cancer cells due to concerted down regulation of Akt. PLoS One. 2013; 8(7):e68973. Thomas S, Thurn KT, Raha P, Chen S, Munster PN. PMID: 23874830; PMCID: PMC3711340.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansCells
    98. Fertility preservation and breast cancer: A complex problem. Oncology (Williston Park). 2013 Jun; 27(6):533-9. Munster PN. PMID: 23909066.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    99. Randomized phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal aromatase inhibitor. J Clin Oncol. 2013 Jun 10; 31(17):2128-35. Yardley DA, Ismail-Khan RR, Melichar B, Lichinitser M, Munster PN, Klein PM, Cruickshank S, Miller KD, Lee MJ, Trepel JB. PMID: 23650416; PMCID: PMC4881332.
      View in: PubMed   Mentions: 191     Fields:    Translation:HumansCTClinical Trials
    100. Temsirolimus combined with sorafenib in hepatocellular carcinoma: a phase I dose-finding trial with pharmacokinetic and biomarker correlates. Ann Oncol. 2013 Jul; 24(7):1900-1907. Kelley RK, Nimeiri HS, Munster PN, Vergo MT, Huang Y, Li CM, Hwang J, Mulcahy MF, Yeh BM, Kuhn P, Luttgen MS, Grabowsky JA, Stucky-Marshall L, Korn WM, Ko AH, Bergsland EK, Benson AB, Venook AP. PMID: 23519998; PMCID: PMC3690907.
      View in: PubMed   Mentions: 32     Fields:    Translation:HumansCellsCTClinical Trials
    101. Developing safety criteria for introducing new agents into neoadjuvant trials. Clin Cancer Res. 2013 Jun 01; 19(11):2817-23. DeMichele A, Berry DA, Zujewski J, Hunsberger S, Rubinstein L, Tomaszewski JE, Kelloff G, Perlmutter J, Buxton M, Lyandres J, Albain KS, Benz C, Chien AJ, Haluska P, Leyland-Jones B, Liu MC, Munster P, Olopade O, Park JW, Parker BA, Pusztai L, Tripathy D, Rugo H, Yee D, Esserman L. PMID: 23470967; PMCID: PMC4096560.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    102. Multicenter phase 1 trial of intraventricular immunochemotherapy in recurrent CNS lymphoma. Blood. 2013 Jan 31; 121(5):745-51. Rubenstein JL, Li J, Chen L, Advani R, Drappatz J, Gerstner E, Batchelor T, Krouwer H, Hwang J, Auerback G, Kadoch C, Lowell C, Munster P, Cha S, Shuman MA, Damon LE. PMID: 23197589; PMCID: PMC3563362.
      View in: PubMed   Mentions: 50     Fields:    Translation:HumansCTClinical Trials
    103. The impact of an electronic health questionnaire on symptom management and behavior reporting for breast cancer survivors. Breast Cancer Res Treat. 2012 Aug; 134(3):1327-35. Bock M, Moore D, Hwang J, Shumay D, Lawson L, Hamolsky D, Esserman L, Rugo H, Chien AJ, Park J, Munster P, Melisko M. PMID: 22798157.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    104. A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab. Breast Cancer Res Treat. 2012 Jun; 133(3):1057-65. Lin NU, Winer EP, Wheatley D, Carey LA, Houston S, Mendelson D, Munster P, Frakes L, Kelly S, Garcia AA, Cleator S, Uttenreuther-Fischer M, Jones H, Wind S, Vinisko R, Hickish T. PMID: 22418700; PMCID: PMC3387495.
      View in: PubMed   Mentions: 78     Fields:    Translation:HumansCTClinical Trials
    105. Randomized trial using gonadotropin-releasing hormone agonist triptorelin for the preservation of ovarian function during (neo)adjuvant chemotherapy for breast cancer. J Clin Oncol. 2012 Feb 10; 30(5):533-8. Munster PN, Moore AP, Ismail-Khan R, Cox CE, Lacevic M, Gross-King M, Xu P, Carter WB, Minton SE. PMID: 22231041; PMCID: PMC3295555.
      View in: PubMed   Mentions: 75     Fields:    Translation:Humans
    106. Phase I clinical trial of the Src inhibitor dasatinib with dacarbazine in metastatic melanoma. Br J Cancer. 2012 Jan 03; 106(1):85-91. Algazi AP, Weber JS, Andrews SC, Urbas P, Munster PN, DeConti RC, Hwang J, Sondak VK, Messina JL, McCalmont T, Daud AI. PMID: 22127285; PMCID: PMC3251861.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansCTClinical Trials
    107. Preclinical and clinical activity of the topoisomerase I inhibitor, karenitecin, in melanoma. Expert Opin Investig Drugs. 2011 Nov; 20(11):1565-74. Munster PN, Daud AI. PMID: 21985236.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansAnimals
    108. Epigenetic modulation: a novel therapeutic target for overcoming hormonal therapy resistance. Epigenomics. 2011 Aug; 3(4):451-70. Raha P, Thomas S, Munster PN. PMID: 22126205.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCells
    109. Phase II study of single-agent bosutinib, a Src/Abl tyrosine kinase inhibitor, in patients with locally advanced or metastatic breast cancer pretreated with chemotherapy. Ann Oncol. 2012 Mar; 23(3):610-617. Campone M, Bondarenko I, Brincat S, Hotko Y, Munster PN, Chmielowska E, Fumoleau P, Ward R, Bardy-Bouxin N, Leip E, Turnbull K, Zacharchuk C, Epstein RJ. PMID: 21700731.
      View in: PubMed   Mentions: 48     Fields:    Translation:HumansCTClinical Trials
    110. A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer. Br J Cancer. 2011 Jun 07; 104(12):1828-35. Munster PN, Thurn KT, Thomas S, Raha P, Lacevic M, Miller A, Melisko M, Ismail-Khan R, Rugo H, Moasser M, Minton SE. PMID: 21559012; PMCID: PMC3111195.
      View in: PubMed   Mentions: 175     Fields:    Translation:HumansCellsCTClinical Trials
    111. Costello and cardio-facio-cutaneous syndromes: Moving toward clinical trials in RASopathies. Am J Med Genet C Semin Med Genet. 2011 May 15; 157C(2):136-46. Rauen KA, Banerjee A, Bishop WR, Lauchle JO, McCormick F, McMahon M, Melese T, Munster PN, Nadaf S, Packer RJ, Sebolt-Leopold J, Viskochil DH. PMID: 21495172; PMCID: PMC4145816.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansCells
    112. Rational therapeutic combinations with histone deacetylase inhibitors for the treatment of cancer. Future Oncol. 2011 Feb; 7(2):263-83. Thurn KT, Thomas S, Moore A, Munster PN. PMID: 21345145; PMCID: PMC3127396.
      View in: PubMed   Mentions: 107     Fields:    Translation:HumansCells
    113. A single supratherapeutic dose of vorinostat does not prolong the QTc interval in patients with advanced cancer. Clin Cancer Res. 2009 Nov 15; 15(22):7077-84. Munster PN, Rubin EH, Van Belle S, Friedman E, Patterson JK, Van Dyck K, Li X, Comisar W, Chodakewitz JA, Wagner JA, Iwamoto M. PMID: 19887475.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCTClinical Trials
    114. Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker. Br J Cancer. 2009 Oct 06; 101(7):1044-50. Munster PN, Marchion D, Thomas S, Egorin M, Minton S, Springett G, Lee JH, Simon G, Chiappori A, Sullivan D, Daud A. PMID: 19738609; PMCID: PMC2768109.
      View in: PubMed   Mentions: 82     Fields:    Translation:HumansCellsCTClinical Trials
    115. Estradiol in breast cancer treatment: reviving the past. JAMA. 2009 Aug 19; 302(7):797-8. Munster PN, Carpenter JT. PMID: 19690316.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    116. Src activation in melanoma and Src inhibitors as therapeutic agents in melanoma. Melanoma Res. 2009 Jun; 19(3):167-75. Homsi J, Cubitt CL, Zhang S, Munster PN, Yu H, Sullivan DM, Jove R, Messina JL, Daud AI. PMID: 19434004.
      View in: PubMed   Mentions: 31     Fields:    Translation:HumansCells
    117. Cognitive functioning in breast cancer survivors: a controlled comparison. Cancer. 2009 Apr 15; 115(8):1776-83. Jim HS, Donovan KA, Small BJ, Andrykowski MA, Munster PN, Jacobsen PB. PMID: 19224550; PMCID: PMC2668740.
      View in: PubMed   Mentions: 43     Fields:    Translation:Humans
    118. Phase II trial of tipifarnib plus neoadjuvant doxorubicin-cyclophosphamide in patients with clinical stage IIB-IIIC breast cancer. Clin Cancer Res. 2009 Apr 15; 15(8):2942-8. Sparano JA, Moulder S, Kazi A, Coppola D, Negassa A, Vahdat L, Li T, Pellegrino C, Fineberg S, Munster P, Malafa M, Lee D, Hoschander S, Hopkins U, Hershman D, Wright JJ, Kleer C, Merajver S, Sebti SM. PMID: 19351752; PMCID: PMC2785076.
      View in: PubMed   Mentions: 32     Fields:    Translation:HumansCTClinical Trials
    119. HDAC2 regulates chromatin plasticity and enhances DNA vulnerability. Mol Cancer Ther. 2009 Apr; 8(4):794-801. Marchion DC, Bicaku E, Turner JG, Schmitt ML, Morelli DR, Munster PN. PMID: 19372552.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansCells
    120. Clinical and biological effects of valproic acid as a histone deacetylase inhibitor on tumor and surrogate tissues: phase I/II trial of valproic acid and epirubicin/FEC. Clin Cancer Res. 2009 Apr 01; 15(7):2488-96. Munster P, Marchion D, Bicaku E, Lacevic M, Kim J, Centeno B, Daud A, Neuger A, Minton S, Sullivan D. PMID: 19318486.
      View in: PubMed   Mentions: 70     Fields:    Translation:HumansCellsCTClinical Trials
    121. A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors. Clin Cancer Res. 2009 Apr 01; 15(7):2552-8. Wong KK, Fracasso PM, Bukowski RM, Lynch TJ, Munster PN, Shapiro GI, Jänne PA, Eder JP, Naughton MJ, Ellis MJ, Jones SF, Mekhail T, Zacharchuk C, Vermette J, Abbas R, Quinn S, Powell C, Burris HA. PMID: 19318484.
      View in: PubMed   Mentions: 100     Fields:    Translation:HumansCTClinical Trials
    122. Potentiation of a topoisomerase I inhibitor, karenitecin, by the histone deacetylase inhibitor valproic acid in melanoma: translational and phase I/II clinical trial. Clin Cancer Res. 2009 Apr 01; 15(7):2479-87. Daud AI, Dawson J, DeConti RC, Bicaku E, Marchion D, Bastien S, Hausheer FA, Lush R, Neuger A, Sullivan DM, Munster PN. PMID: 19318485.
      View in: PubMed   Mentions: 34     Fields:    Translation:HumansAnimalsCellsCTClinical Trials
    123. Histone deacetylase inhibitor induced modulation of anti-estrogen therapy. Cancer Lett. 2009 Aug 08; 280(2):184-91. Thomas S, Munster PN. PMID: 19185986.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansCells
    124. Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma. J Clin Oncol. 2008 Dec 20; 26(36):5896-903. Daud AI, DeConti RC, Andrews S, Urbas P, Riker AI, Sondak VK, Munster PN, Sullivan DM, Ugen KE, Messina JL, Heller R. PMID: 19029422; PMCID: PMC2645111.
      View in: PubMed   Mentions: 258     Fields:    Translation:HumansCTClinical Trials
    125. Phase 2 study of gemcitabine and irinotecan in metastatic breast cancer with correlatives to determine topoisomerase I localization as a predictor of response. Cancer. 2008 Nov 15; 113(10):2646-54. Moulder S, Valkov N, Neuger A, Choi J, Lee JH, Minton S, Munster P, Gump J, Lacevic M, Lush R, Sullivan D. PMID: 18823053.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCTClinical Trials
    126. Activated stat-3 in melanoma. Cancer Control. 2008 Jul; 15(3):196-201. Messina JL, Yu H, Riker AI, Munster PN, Jove RL, Daud AI. PMID: 18596671.
      View in: PubMed   Mentions: 30     Fields:    Translation:HumansCells
    127. Identifying clinically meaningful fatigue with the Fatigue Symptom Inventory. J Pain Symptom Manage. 2008 Nov; 36(5):480-7. Donovan KA, Jacobsen PB, Small BJ, Munster PN, Andrykowski MA. PMID: 18495413; PMCID: PMC2590752.
      View in: PubMed   Mentions: 66     Fields:    Translation:Humans
    128. Exploring the differential experience of breast cancer treatment-related symptoms: a cluster analytic approach. Support Care Cancer. 2008 Aug; 16(8):925-33. Gwede CK, Small BJ, Munster PN, Andrykowski MA, Jacobsen PB. PMID: 18043948; PMCID: PMC2892385.
      View in: PubMed   Mentions: 29     Fields:    Translation:Humans
    129. Fatigue after treatment for early stage breast cancer: a controlled comparison. Cancer. 2007 Oct 15; 110(8):1851-9. Jacobsen PB, Donovan KA, Small BJ, Jim HS, Munster PN, Andrykowski MA. PMID: 17847016; PMCID: PMC2646727.
      View in: PubMed   Mentions: 32     Fields:    Translation:Humans
    130. Phase I trial of poly-L-glutamate camptothecin (CT-2106) administered weekly in patients with advanced solid malignancies. Clin Cancer Res. 2007 Oct 01; 13(19):5855-61. Homsi J, Simon GR, Garrett CR, Springett G, De Conti R, Chiappori AA, Munster PN, Burton MK, Stromatt S, Allievi C, Angiuli P, Eisenfeld A, Sullivan DM, Daud AI. PMID: 17908979.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansCTClinical Trials
    131. Physical symptoms/side effects during breast cancer treatment predict posttreatment distress. Ann Behav Med. 2007 Oct; 34(2):200-8. Jim HS, Andrykowski MA, Munster PN, Jacobsen PB. PMID: 17927558.
      View in: PubMed   Mentions: 26     Fields:    Translation:Humans
    132. Pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors: correlations with clinical characteristics and safety. Cancer Chemother Pharmacol. 2008 Jun; 62(1):97-109. Guo F, Letrent SP, Munster PN, Britten CD, Gelmon K, Tolcher AW, Sharma A. PMID: 17805538.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    133. Utility of a cognitive-behavioral model to predict fatigue following breast cancer treatment. Health Psychol. 2007 Jul; 26(4):464-72. Donovan KA, Small BJ, Andrykowski MA, Munster P, Jacobsen PB. PMID: 17605566; PMCID: PMC2383279.
      View in: PubMed   Mentions: 62     Fields:    Translation:Humans
    134. Discussion of fertility preservation with newly diagnosed patients: oncologists' views. J Cancer Surviv. 2007 Jun; 1(2):146-55. Quinn GP, Vadaparampil ST, Gwede CK, Miree C, King LM, Clayton HB, Wilson C, Munster P. PMID: 18648955.
      View in: PubMed   Mentions: 77     Fields:    Translation:Humans
    135. First study of the safety, tolerability, and pharmacokinetics of CP-724,714 in patients with advanced malignant solid HER2-expressing tumors. Clin Cancer Res. 2007 Feb 15; 13(4):1238-45. Munster PN, Britten CD, Mita M, Gelmon K, Minton SE, Moulder S, Slamon DJ, Guo F, Letrent SP, Denis L, Tolcher AW. PMID: 17317835.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCTClinical Trials
    136. ABCG2 expression, function, and promoter methylation in human multiple myeloma. Blood. 2006 Dec 01; 108(12):3881-9. Turner JG, Gump JL, Zhang C, Cook JM, Marchion D, Hazlehurst L, Munster P, Schell MJ, Dalton WS, Sullivan DM. PMID: 16917002; PMCID: PMC1895461.
      View in: PubMed   Mentions: 86     Fields:    Translation:HumansCellsCTClinical Trials
    137. Increased bioavailability of intravenous versus oral CI-1033, a pan erbB tyrosine kinase inhibitor: results of a phase I pharmacokinetic study. Clin Cancer Res. 2006 Aug 01; 12(15):4645-51. Simon GR, Garrett CR, Olson SC, Langevin M, Eiseman IA, Mahany JJ, Williams CC, Lush R, Daud A, Munster P, Chiappori A, Fishman M, Bepler G, Lenehan PF, Sullivan DM. PMID: 16899614.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    138. Sequential oral 9-nitrocamptothecin and etoposide: a pharmacodynamic- and pharmacokinetic-based phase I trial. Mol Cancer Ther. 2006 Aug; 5(8):2130-7. Simon GR, Lush RM, Gump J, Tetteh L, Williams C, Cantor A, Antonia S, Garrett C, Rocha-Lima C, Fishman M, Sullivan DM, Munster PN. PMID: 16928835.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    139. Overall and progression-free survival in metastatic melanoma: analysis of a single-institution database. Cancer Control. 2006 Jul; 13(3):211-7. Khan MA, Andrews S, Ismail-Khan R, Munster PN, Brem S, King J, Reintgen DS, Sondak VK, Daud AI. PMID: 16885917.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    140. Targeted inhibition of farnesyltransferase in locally advanced breast cancer: a phase I and II trial of tipifarnib plus dose-dense doxorubicin and cyclophosphamide. J Clin Oncol. 2006 Jul 01; 24(19):3013-8. Sparano JA, Moulder S, Kazi A, Vahdat L, Li T, Pellegrino C, Munster P, Malafa M, Lee D, Hoschander S, Hopkins U, Hershman D, Wright JJ, Sebti SM. PMID: 16769985.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCTClinical Trials
    141. Arzoxifene: the development and clinical outcome of an ideal SERM. Expert Opin Investig Drugs. 2006 Mar; 15(3):317-26. Munster PN. PMID: 16503767.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansAnimals
    142. In vivo synergy between topoisomerase II and histone deacetylase inhibitors: predictive correlates. Mol Cancer Ther. 2005 Dec; 4(12):1993-2000. Marchion DC, Bicaku E, Daud AI, Sullivan DM, Munster PN. PMID: 16373714.
      View in: PubMed   Mentions: 31     Fields:    Translation:HumansAnimalsCells
    143. Cognitive functioning after adjuvant chemotherapy and/or radiotherapy for early-stage breast carcinoma. Cancer. 2005 Dec 01; 104(11):2499-507. Donovan KA, Small BJ, Andrykowski MA, Schmitt FA, Munster P, Jacobsen PB. PMID: 16247788; PMCID: PMC2653200.
      View in: PubMed   Mentions: 40     Fields:    Translation:Humans
    144. Synergistic interaction between histone deacetylase and topoisomerase II inhibitors is mediated through topoisomerase IIbeta. Clin Cancer Res. 2005 Dec 01; 11(23):8467-75. Marchion DC, Bicaku E, Turner JG, Daud AI, Sullivan DM, Munster PN. PMID: 16322310.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansCells
    145. Chinese herbal formula, Bing De Ling, enhances antitumor effects and ameliorates weight loss induced by 5-fluorouracil in the mouse CT26 tumor model. DNA Cell Biol. 2005 Jul; 24(7):470-5. Xu Q, Brabham JG, Zhang S, Munster P, Fields K, Zhao RJ, Yu H. PMID: 16008516.
      View in: PubMed   Mentions: 4     Fields:    Translation:AnimalsCells
    146. Valproic acid alters chromatin structure by regulation of chromatin modulation proteins. Cancer Res. 2005 May 01; 65(9):3815-22. Marchion DC, Bicaku E, Daud AI, Sullivan DM, Munster PN. PMID: 15867379.
      View in: PubMed   Mentions: 82     Fields:    Translation:HumansAnimalsCells
    147. Phase II trial of karenitecin in patients with malignant melanoma: clinical and translational study. Clin Cancer Res. 2005 Apr 15; 11(8):3009-16. Daud A, Valkov N, Centeno B, Derderian J, Sullivan P, Munster P, Urbas P, Deconti RC, Berghorn E, Liu Z, Hausheer F, Sullivan D. PMID: 15837755.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCellsCTClinical Trials
    148. Sequence-specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamic acid. J Cell Biochem. 2004 May 15; 92(2):223-37. Marchion DC, Bicaku E, Daud AI, Richon V, Sullivan DM, Munster PN. PMID: 15108350.
      View in: PubMed   Mentions: 56     Fields:    Translation:HumansCells
    149. Phase II, randomized, double-blind study of two dose levels of arzoxifene in patients with locally advanced or metastatic breast cancer. J Clin Oncol. 2003 Mar 15; 21(6):1007-14. Buzdar A, O'Shaughnessy JA, Booser DJ, Pippen JE, Jones SE, Munster PN, Peterson P, Melemed AS, Winer E, Hudis C. PMID: 12637464.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCTClinical Trials
    150. Improving breast cancer care. Cancer Control. 2002 Nov-Dec; 9(6):455-6. Munster PN. PMID: 12514562.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    151. Chemotherapy-induced amenorrhea and fertility in women undergoing adjuvant treatment for breast cancer. Cancer Control. 2002 Nov-Dec; 9(6):466-72. Minton SE, Munster PN. PMID: 12514564.
      View in: PubMed   Mentions: 30     Fields:    Translation:Humans
    152. Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2. Oncogene. 2002 Feb 14; 21(8):1159-66. Basso AD, Solit DB, Munster PN, Rosen N. PMID: 11850835; PMCID: PMC3221005.
      View in: PubMed   Mentions: 82     Fields:    Translation:HumansAnimalsCells
    153. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells. Cancer Res. 2001 Dec 01; 61(23):8492-7. Munster PN, Troso-Sandoval T, Rosen N, Rifkind R, Marks PA, Richon VM. PMID: 11731433.
      View in: PubMed   Mentions: 107     Fields:    Translation:HumansCells
    154. Tamoxifen vs the aromatase inhibitors: news from San Antonio, 2001. Cancer Control. 2001 Nov-Dec; 8(6):478-9. Munster PN, Horton J. PMID: 11807416.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    155. Predictive factor for the response to adjuvant therapy with emphasis in breast cancer. Breast Cancer Res. 2001; 3(6):361-4. Munster PN, Norton L. PMID: 11737886; PMCID: PMC138701.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    156. New drugs in gynecologic cancer. Curr Treat Options Oncol. 2001 Apr; 2(2):119-28. Daud A, Munster P, Munster P, Spriggs DR. PMID: 12057130.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    157. A small molecule designed to bind to the adenine nucleotide pocket of Hsp90 causes Her2 degradation and the growth arrest and differentiation of breast cancer cells. Chem Biol. 2001 Mar; 8(3):289-99. Chiosis G, Timaul MN, Lucas B, Munster PN, Zheng FF, Sepp-Lorenzino L, Rosen N. PMID: 11306353.
      View in: PubMed   Mentions: 69     Fields:    Translation:HumansCells
    158. Update on the management of advanced breast cancer. Oncology (Williston Park). 1999 May; 13(5):647-58; discussion 660, 663-4. Fornier M, Munster P, Seidman AD. PMID: 10356685.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    Pamela's Networks
    Concepts (604)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (118)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCSF Profiles is managed by the UCSF Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number UL1 TR000004) at the National Institutes of Health (NIH).

    We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use. This site is running Profiles RNS version UCSF-v3.1.0-6-g69de2244 on PROFILES-PWEB04.

    Copyright © The Regents of the University of California.